Ticagrelor 60 mg

DRUG7 trials

Conditions

Acute Coronary SyndromeAtherothrombosisCardiovascular DeathChronic Coronary SyndromeCoronary Artery DiseaseDiabetes MellitusDiabetes Mellitus, Type 2Myocardial Infarction

Phase 3

Prevention of Cardiovascular Events (eg, Death From Heart or Vascular Disease, Heart Attack, or Stroke) in Patients With Prior Heart Attack Using Ticagrelor Compared to Placebo on a Background of Aspirin

CompletedNCT01225562

AstraZenecaAtherothrombosis, Cardiovascular Death, Myocardial Infarction +1

Start: 2010-10-31End: 2014-12-31Updated: 2016-01-25

A Study Comparing Cardiovascular Effects of Ticagrelor Versus Placebo in Patients With Type 2 Diabetes Mellitus

CompletedNCT01991795

AstraZenecaDiabetes Mellitus, Type 2

Start: 2014-02-10End: 2019-01-25Updated: 2020-03-18

Effectiveness of Lower Maintenance Dose of Ticagrelor Early After Myocardial Infarction (ELECTRA) Pilot Study

CompletedNCT03251859

Collegium Medicum w BydgoszczyMyocardial Infarction

Start: 2017-08-11End: 2018-02-23Updated: 2023-04-21

Platelet Inhibition With Ticagrelor 60 mg Versus Ticagrelor 90 mg in Elderly Patients With ACS

CompletedNCT04739384

Federico II UniversityAcute Coronary Syndrome, Coronary Artery Disease, Myocardial Infarction +2

Start: 2021-04-01End: 2022-06-20Updated: 2022-07-07

Phase 4

Low Dose Ticagrelor Versus Low Dose Prasugrel in Patients With Prior Myocardial Infarction

CompletedNCT03387826

Attikon HospitalCoronary Artery Disease, Diabetes Mellitus, Myocardial Infarction +1

Start: 2018-01-11End: 2019-01-31Updated: 2019-03-05

Ticagrelor Monotherapy Compared to Aspirin Monotherapy in Patients With History of ACS

CompletedNCT03881943

The University of Hong KongAcute Coronary Syndrome

Start: 2017-01-31End: 2018-12-21Updated: 2019-03-20

Short-Term Dual Antiplatelet Therapy With Early Transi-tion to Low-dose Antiplatelet Monotherapy Using Ti-cagRelor in Chronic Coronary Artery Disease

Not yet recruitingNCT07080684

University of MessinaChronic Coronary Syndrome

Start: 2025-12-01End: 2027-09-30Target: 1000Updated: 2025-07-23

2025-11-16

Polygenic risk score for coronary artery disease across the spectrum of atherosclerotic disease

European Journal of Preventive Cardiology2025-10-27

Statistical approaches for systematically missing covariates in individual participant data meta-analysis: insights and applications using 5 large cardiovascular trials

American Journal of Epidemiology2025-10-08

Ticagrelor 60 vs. 90 mg in elderly ACS patients undergoing PCI: a randomized, crossover trial

European Heart Journal - Cardiovascular Pharmacotherapy2024-07-186 citations

Limb Outcomes With Ticagrelor Plus Aspirin in Patients With Diabetes Mellitus and Atherosclerosis.

2024-04-017 citations

Patient selection for long-term secondary prevention with ticagrelor: insights from PEGASUS-TIMI 54

European Heart Journal2022-11-1124 citations

External applicability of the Effect of ticagrelor on Health Outcomes in diabEtes Mellitus patients Intervention Study (THEMIS) trial: An analysis of patients with diabetes and coronary artery disease in the REduction of Atherothrombosis for Continued Health (REACH) registry.

2022-10-19

Blood pressure and clinical outcomes in patients with diabetes and stable coronary artery disease in THEMIS

European Heart Journal2022-10-01

Multi-Omics Signatures Link to Ticagrelor Effects on Vascular Function in Patients With Acute Coronary Syndrome

Arteriosclerosis Thrombosis and Vascular Biology2022-04-078 citations

Platelet Inhibition with Ticagrelor 60 mg Versus 90 mg Twice Daily in Elderly Patients with Acute Coronary Syndrome: Rationale and Design of the PLINY THE ELDER Trial.

2022-01-208 citations

Abstract 9330: Machine Learning Can Enable the Automation of Clinical Endpoint Adjudication

Circulation2021-11-16

Long‐Term Ticagrelor in Patients With Prior Coronary Stenting in the PEGASUS‐TIMI 54 Trial

Journal of the American Heart Association2021-08-2116 citations

Predictors, Type, and Impact of Bleeding on the Net Clinical Benefit of Long‐Term Ticagrelor in Stable Patients With Prior Myocardial Infarction

Journal of the American Heart Association2021-02-0931 citations

Assessment of The High risk and unmEt Need in patients with CAD and type 2 diabetes (ATHENA): US healthcare resource use, cost, and burden of illness in a commercially insured population.

2021-01-202 citations

403-P: Impact of Diabetes-Related Factors and Background Antihyperglycemic Therapy on the Efficacy and Safety of Ticagrelor Added to Aspirin: Insights from the THEMIS Trial

Diabetes2020-06-01

Caffeinated Beverage Intake, Dyspnea With Ticagrelor, and Cardiovascular Outcomes: Insights From the PEGASUS-TIMI 54 Trial.

2020-05-156 citations

Assessment of the high risk and unmet need in patients with CAD and type 2 diabetes (ATHENA): US healthcare resource utilization, cost and burden of illness in the Diabetes Collaborative Registry

Endocrinology Diabetes & Metabolism2020-05-078 citations

Gut Microbiota-Dependent Trimethylamine N-oxide and Cardiovascular Outcomes in Patients With Prior Myocardial Infarction: A Nested Case Control Study From the PEGASUS-TIMI 54 Trial.

2020-05-0533 citations

Long-term ticagrelor for secondary prevention in patients with prior myocardial infarction and no history of coronary stenting: insights from PEGASUS-TIMI 54

European Heart Journal2019-11-0237 citations

2207Cardiovascular outcome in THEMIS -like type 2 diabetes patients in Sweden: a nationwide observational study

European Heart Journal2019-10-011 citations

21 more papers not shown

Ticagrelor 60 mg

Sponsors

Conditions

Phase 3

Phase 4

Related Papers